Angelo DeMattos

1.6k total citations
27 papers, 1.3k citations indexed

About

Angelo DeMattos is a scholar working on Transplantation, Surgery and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Angelo DeMattos has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Transplantation, 12 papers in Surgery and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Angelo DeMattos's work include Renal Transplantation Outcomes and Treatments (20 papers), Organ Transplantation Techniques and Outcomes (8 papers) and Neurological Complications and Syndromes (6 papers). Angelo DeMattos is often cited by papers focused on Renal Transplantation Outcomes and Treatments (20 papers), Organ Transplantation Techniques and Outcomes (8 papers) and Neurological Complications and Syndromes (6 papers). Angelo DeMattos collaborates with scholars based in United States, United Kingdom and Canada. Angelo DeMattos's co-authors include Takeshi F. Andoh, William M. Bennett, Mary M. Meyer, William M. Bennett, Ali J. Olyaei, Douglas J. Norman, John M. Barry, Fadi G. Hage, Ami E. Iskandrian and Gilbert J. Zoghbi and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Angelo DeMattos

27 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angelo DeMattos United States 16 654 398 212 200 197 27 1.3k
Roberto Marcén Spain 16 386 0.6× 269 0.7× 242 1.1× 111 0.6× 390 2.0× 38 1.1k
A B Leichtman United States 9 1.0k 1.5× 638 1.6× 152 0.7× 101 0.5× 164 0.8× 13 1.4k
Celestino Piñera Spain 21 624 1.0× 466 1.2× 143 0.7× 78 0.4× 483 2.5× 61 1.3k
Michael Cardi United States 17 730 1.1× 656 1.6× 120 0.6× 89 0.4× 239 1.2× 24 1.2k
Michael E. Falkenhain United States 17 829 1.3× 541 1.4× 112 0.5× 257 1.3× 503 2.6× 21 1.6k
T. Wujciak Germany 14 796 1.2× 599 1.5× 88 0.4× 103 0.5× 139 0.7× 24 1.3k
R. Palomar Spain 17 594 0.9× 406 1.0× 115 0.5× 67 0.3× 232 1.2× 49 1.1k
Manuel Arias Spain 23 534 0.8× 360 0.9× 235 1.1× 67 0.3× 556 2.8× 63 1.4k
A. Aroldi Italy 15 333 0.5× 166 0.4× 208 1.0× 179 0.9× 198 1.0× 44 849
Gema Fernández‐Fresnedo Spain 27 1.2k 1.9× 743 1.9× 261 1.2× 141 0.7× 637 3.2× 116 2.3k

Countries citing papers authored by Angelo DeMattos

Since Specialization
Citations

This map shows the geographic impact of Angelo DeMattos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo DeMattos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo DeMattos more than expected).

Fields of papers citing papers by Angelo DeMattos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo DeMattos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo DeMattos. The network helps show where Angelo DeMattos may publish in the future.

Co-authorship network of co-authors of Angelo DeMattos

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo DeMattos. A scholar is included among the top collaborators of Angelo DeMattos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo DeMattos. Angelo DeMattos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wiseman, Alexander C., Enver Akalin, Darshana M. Dadhania, et al.. (2020). Defining the roles and responsibilities of the kidney transplant medical director: A necessary step for future training, mentoring, and professional development. American Journal of Transplantation. 21(4). 1556–1563. 4 indexed citations
2.
Singh, Gagan D., Ehrin J. Armstrong, Angelo DeMattos, et al.. (2014). Abstract 17044: Percutaneous Coronary Intervention and Dual Antiplatelet Therapy Are Safe Prior to Kidney Transplantation. Circulation. 130. 1 indexed citations
3.
Hage, Fadi G., Rajesh Venkataraman, Gilbert J. Zoghbi, et al.. (2009). The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology. 53(23). 2129–2140. 167 indexed citations
4.
Hippen, Benjamin, et al.. (2005). Association of CD20+ Infiltrates with Poorer Clinical Outcomes in Acute Cellular Rejection of Renal Allografts. American Journal of Transplantation. 5(9). 2248–2252. 123 indexed citations
5.
Olyaei, Ali J., Angelo DeMattos, & William M. Bennett. (2005). Cardiovascular complications of immunosuppressive agents in renal transplant recipients. Expert Opinion on Drug Safety. 4(1). 29–44. 6 indexed citations
6.
Keith, D.S., et al.. (2004). Effect of Donor Recipient Age Match on Survival after First Deceased Donor Renal Transplantation. Journal of the American Society of Nephrology. 15(4). 1086–1091. 53 indexed citations
7.
Norman, Douglas J., et al.. (2001). Use of A2 kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade. Transplantation Proceedings. 33(7-8). 3327–3330. 5 indexed citations
8.
Olyaei, Ali J., et al.. (2001). Use of basiliximab and daclizumab in kidney transplantation. Progress in Transplantation. 11(1). 33–39. 17 indexed citations
9.
DeMattos, Angelo & Hugo R. Rosen. (2000). Histopathological Features of Hepatitis C in Renal Transplant Candidates. Transplantation 2000; 69: 1479.. Transplantation. 69(7). 1236–1237. 1 indexed citations
10.
Olyaei, Ali J., Angelo DeMattos, & William M. Bennett. (2000). Renal toxicity of protease inhibitors. Current Opinion in Nephrology & Hypertension. 9(5). 473–476. 21 indexed citations
11.
Olyaei, Ali J., Angelo DeMattos, & William M. Bennett. (1999). The impact of generic drugs on the cost of transplantation medical care. Transplantation Proceedings. 31(3). 31S–34S. 3 indexed citations
12.
Olyaei, Ali J., Angelo DeMattos, & William M. Bennett. (1999). A Practical Guide to the Management of Hypertension in Renal Transplant Recipients. Drugs. 58(6). 1011–1027. 47 indexed citations
13.
Olyaei, Ali J., et al.. (1998). Interaction Between Tacrolimus and Nefazodone in a Stable Renal Transplant Recipient. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(6). 1356–1359. 26 indexed citations
14.
Alkhunaizi, Ahmed M., Ali J. Olyaei, John M. Barry, et al.. (1998). EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN IN RENAL TRANSPLANTATION1. Transplantation. 66(4). 533–534. 38 indexed citations
15.
Olyaei, Ali J., et al.. (1997). Switching Between Cyclosporin Formulations What are the Risks?. Drug Safety. 16(6). 366–373. 21 indexed citations
16.
Barry, John M., et al.. (1996). Cadaver kidney transplantation in patients more than 65 years old. World Journal of Urology. 14(4). 243–8. 9 indexed citations
17.
Bennett, William M., et al.. (1996). Chronic cyclosporine nephropathy in renal transplantation.. PubMed. 28(4). 2100–3. 16 indexed citations
18.
Bennett, William M., et al.. (1996). Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney International. 50(4). 1089–1100. 375 indexed citations
19.
Roth, David, Keith Zucker, Robert Cirocco, et al.. (1994). The impact of hepatitis C virus infection on renal allograft recipients. Kidney International. 45(1). 238–244. 145 indexed citations
20.
DeMattos, Angelo, et al.. (1993). OKT3 for treatment of rejection in renal transplantation. Clinical Transplantation. 7(4pt2). 374–381. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberto Marcén Breakdown of academic impact, for papers by A B Leichtman Breakdown of academic impact, for papers by Celestino Piñera Breakdown of academic impact, for papers by Michael Cardi Breakdown of academic impact, for papers by Michael E. Falkenhain Breakdown of academic impact, for papers by T. Wujciak Breakdown of academic impact, for papers by R. Palomar Breakdown of academic impact, for papers by Manuel Arias Breakdown of academic impact, for papers by A. Aroldi Breakdown of academic impact, for papers by Gema Fernández‐Fresnedo
Rankless by CCL
2026